Antibiotics for community acquired pneumonia in adult outpatients (Q24240033)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Antibiotics for community acquired pneumonia in adult outpatients (English)

0 references

0 references

0 references

2

Theo JM Verheij

Theo Jm

Verheij

1 reference

26 October 2023

Lise M Bjerre

1

Lise M

Bjerre

1 reference

26 October 2023

Michael M Kochen

series ordinal

3

author given names

Michael M

author last names

Kochen

1 reference

26 October 2023

7 October 2009

0 references

published in

0 references

cites work

Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicenter, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Sparfloxacin as alternative treatment to standard therapy for community-acquired bacteremic pneumococcal pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Azithromycin versus comparative therapy for the treatment of community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Update to the Latin American Thoracic Society (ALAT) Recommendations on Community-Acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

2004 update of BTS pneumonia guidelines: what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Community-acquired pneumonia: the annual cost to the National Health Service in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

S3-guideline on ambulant acquired pneumonia and deep airway infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Executive summary of the Gulf Cooperation Council practice guidelines for the management of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Severe Community-acquired Pneumonia: Epidemiology and Prognostic Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Prospective study of the aetiology and outcome of pneumonia in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Guidelines for the management of adult lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Antibiotics for community acquired pneumonia in adult outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

A randomized double-blind controlled trial of roxithromycin and cefaclor in the treatment of acute lower respiratory tract infections in general practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. The British Thoracic Society Research Committee and The Public Health Laboratory Service

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Comparison of spiramycin and doxycycline in the treatment of lower respiratory infections in general practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Ofloxacin once daily versus twice daily in community-acquired pneumonia and acute exacerbation of chronic bronchitis. A randomized multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021

Comparison of Clarithromycin and Amoxicillin/Clavulanic Acid for Community-Acquired Pneumonia in an Era of Drug-Resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB3

7 January 2021